Apellis Pharmaceuticals CFO Timothy Sullivan Transfers Shares to Irrevocable Trust

This Form 4 filing reports that Timothy Sullivan, Chief Financial Officer of Apellis Pharmaceuticals, transferred 11,096 shares of common stock to The Timothy E Sullivan Irrevocable Trust of 2023 on April 17, 2026. The transaction was a gift (transaction code G) with no monetary consideration. Following the transfer, Sullivan's direct ownership decreased to 140,945 shares, while his indirect ownership through the trust increased to 71,492 shares. The filing notes that Patrick O. Collins serves as trustee of the irrevocable trust, and Sullivan disclaims beneficial ownership of the trust-held shares except to the extent of his pecuniary interest. This represents a restructuring of Sullivan's ownership position rather than a market transaction, as the shares were transferred at $0 per share. The filing was signed by attorney-in-fact David Watson on April 20, 2026.